Saphenous vein graft (SVG) angioplasty is associated with frequent periprocedural complications due to distal embolization and a high risk of restenosis. The purpose of this single-center, retrospective study was to determine the distal embolization incidences and outcomes of stenting for SVG lesions and percutaneous angioplasty for in-stent restenosis of these SVGs.
alternative to repeat CABG. 2, 3) However, SVG angioplasty is associated with frequent periprocedural complications due to distal embolization and high risk of restenosis. [4] [5] [6] Therefore, new strategies were developed to minimize risk of distal embolization and to reduce late restenosis. [7] [8] [9] Distal embolic protection devices have been shown to reduce the incidence of distal embolization in percutaneous coronary intervention of SVG lesions. [10] [11] [12] Recently in some studies, it was claimed that stent implantation alone to SVG lesions may be able to prevent distal embolization and reduce late cardiac events. [13] [14] [15] [16] [17] Also, distal embolic protection may not be necessary during percutaneous intervention of in-stent restenosis (ISR) in SVGs. 18) Therefore, we planned a retrospective study to determine the distal embolization incidences and procedural outcomes of SVG stenting; and at follow-up, percutaneous angioplasty for ISR of these SVGs in our institution.
METHODS
This study included 48 consecutive patients who had prior CABG and underwent stent deployment to SVG lesions detected at our institution over a period of 4 years. All patients were selected for treatment of the angina pectoris or provocable ischemia documented by noninvasive testing. Baseline clinical demographic data and in-hospital events were obtained by independent hospital chart review. Table I lists the baseline characteristics of these patients.
Stent implantation was performed by standard techniques using a femoral approach. The target lesion was usually predilated with a balloon catheter to facilitate stent delivery. Clopidogrel (75 mg) tb for 4 weeks was given to all patients who underwent stent deployment. Angiographic success was defined as < 50% residual diameter stenosis with Thrombolysis in Myocardial Infarction (TIMI) flow grade 3. Clinical success was defined as angiographic success without in-hospital complications (death, Qwave myocardial infarction (MI), emergency CABG). Emergency CABG was defined as CABG performed within 24 hours of the index percutaneous procedure.
All patients underwent a pre-and postintervention 12-lead electrocardiogram and blood samples were routinely acquired from patients after the procedure for creatine kinase (CK) and its MB fraction enzyme at intervals. Q-wave MI was defined as the presence of new Q waves on the postprocedure electrocardiography and a corresponding rise by at least threefold above normal limits of the serum CK-MB fraction. Non-Q wave MI was defined as a rise by at least threefold above normal limits of the serum CK-MB fraction without the appearance of new Q waves. Unstable angina pectoris and acute MI were accepted as acute coronary syndrome.
All angiograms recorded at the time of intervention were reviewed. Quantitative coronary angiographic analysis was performed by an independent observer blinded to the clinical data. Quantitative analysis was performed using an edgedetection algorithm in the projection showing the most severe stenosis in an unforeshortened view, using a contrast-filled catheter as a reference standard (Medcon Telemedicine Technology, version 1.900, Israel). The following measurements were obtained: (1) length of the lesion; (2) reference vessel diameter; and (3) pre-and postintervention minimal luminal diameter. The percentage diameter stenosis was calculated using the minimal and reference vessel diameters. Distal embolization was present when there was "no" reflow, slow flow, or an abrupt cutoff in one of the distal coronary artery branches. No-reflow was defined as TIMI 0 to 1 flow and slow flow as TIMI 2 flow. Intravascular ultrasound was not routinely used.
Follow-up angiography was performed only for recurrent symptoms. Restenosis was defined as ≥ 50% diameter stenosis at the intervention site on follow-up angiography.
Statistical analysis was performed using an SPSS software package (version 10.0, SPSS Inc, Chicago, Illinois, USA). Categoric variables are expressed as counts and percentages. Categoric variables were compared using the Pearson Chi-square test or Fisher's exact test. Continuous variables are presented as the mean ± SD. The potential risk factors for ISR and distal embolization were analysed, odds ratio and 95% confidence intervals were calculated. All hypothesis testing was 2-tailed. A P value of <0.05 was considered significant.
RESULTS
The study population included 48 patients with a mean age of 62 ± 7 years and 92% were men. The baseline clinical characteristics of the patients are listed in Table 1 . Indications for revascularization included stable angina in 34 patients (71%), unstable angina in 11 patients (23%), and acute MI in 3 patients (6%).
Stent deployment was performed in 48 lesions in the 48 patients. The lesion characteristics with quantitative measurements are listed in Table II . Various stent types were used: Helistent (n = 21; Rueil-Malmaison, Cedex, France), Jostent (n = 19; JOMED, Rangendingen, Germany), and NIR primo stent (n = 10; ScimedBoston Scientific, Minneapolis, MN, USA). Multiple stents were inserted in 2 patients.
The glycoprotein IIb/IIIa inhibitor tirofiban was used in 27 (56%) patients. No reflow (TIMI 1 flow) was observed in 2 patients and slow flow (TIMI 2 flow) was observed in 3 patients. Overall, no reflow/slow flow phenomenon occurred in 5 (10%) patients. There was no case of abrupt closure. Angiographic success was achieved in 98% of the patients. All patients survived after stent implantation, but 2 patients experienced non Q-wave MI and 1 patient experienced Q- Table III . The length of stay in hospital was 3.8 ± 2.4 days. A total of 31 (65%) patients underwent repeat angiography for recurrent angina. The angiography was conducted at a mean time of 9.7 ± 4.3 months. No patient had acute MI and 9 patients had unstable angina pectoris. Angiographic evidence of restenosis was observed in 11 (23%) patients. The preprocedure diameter stenosis was 66.5 ± 11.8%. Lesions were treated with balloon angioplasty alone and a new stent was required in 2 patients. The minimal lumen diameter increased from 2.6 ± 1.1 mm to 3.1 ± 0.3 mm after angioplasty. A glycoprotein IIb/IIIa inhibitor (tirofiban) was used in 7 of 11 (64%) patients. The angiographic success rate was 100% and the procedural success rate was 100%. There were no cases of no reflow/slow flow. Restenosis was observed, particularly in patients with diabetes mellitus, hypercholesterolemia and acute coronary syndrome (Table IV) .
At 8 months follow-up, only 3 of these 11 patients complained of recurrent angina and 1 patient had syncope. They underwent coronary angiography and angiographic restenosis was observed in 2 patients. 
DISCUSSION
Percutaneous angioplasty for the treatment of degenerated SVGs has been performed for the last 20 years. Distal embolization is a frequent complication of percutaneous intervention in degenerated SVGs. 4, 6) Distal embolization may result in no reflow/slow flow phenomenon which is associated with a high mortality and risk of acute MI. 19) After percutaneous intervention of a lesion, no reflow/slow flow may be seen because of distal embolization of atherosclerotic debris, spasm of the distal microcirculation, and thrombotic clusters. 20) In a retrospective study, Hong, et al reported that the risk of distal embolization with balloon angioplasty of SVG lesions increases with more instrumentation within the graft, especially with bulky devices. They recommended increased stent use to reduce mortality and target lesion revascularization. 13) Holmes, et al proposed that atherectomy of de novo SVG lesions was associated with increased distal embolization in addition to improved initial angiographic success. 4) Therefore, stent implantation in patients with SVG lesions can be achieved with a high rate of procedural success and improves short and long-term outcomes.
7,14-17) Bhargava, et al studied the procedural results of multiple SVG stenting and observed distal embolization in 3.4% of patients in the single SVG group and 0.9% of patients in the multiple SVG group. 17) Kuroda, et al studied 51 patients who underwent stenting of the bypass graft and observed distal embolization in 6 grafts (13.6%).
21) Also, Savage, et al observed less non-Q wave MI after SVG stenting compared to balloon angioplasty to SVGs (2% versus 7%, P = 0.10) and the procedural success rate after SVG stenting was 97%. 14) In another study, 106 patients underwent SVG stenting and embolization of graft material into the native coronary artery was noted in only 3 patients (2.8%). 22) Consistent with previous studies, procedural success was high after stent implantation in our study (96%). Also, no reflow/slow flow phenomenon was observed only in 5 (10%) patients.
There are many anatomical and histological differences between SVGs and native coronary artery disease. The factors separating SVGs from native coronary arteries are increased intraluminal pressure, graft wall ischemia, thrombosis or fibrin deposition from ischemia or trauma or both, with secondary repair of the damaged endothelium and intima. 23) After angioplasty, the graft response varies in relation to the age of the graft. [23] [24] [25] In the first month, graft failure is usually due to thrombosis secondary to technical operative factors. In the first year, intimal thickening occurs. After one year, stenosis is usually composed of atherosclerotic plaque with intimal fibrous thickening like native coronary arteries. 23) In the present study, graft age was 9.1 ± 3.8 years. Therefore, atherosclerotic plaque with intimal fibrous thickening must be a major component of occlusion. The reason for the limited number of no reflow/slow flow phenomenon may be explained by this data.
In patients with distal embolization, 2 had acute MI and 2 had unstable angina pectoris. In these patients, a high thrombus burden was expected. We observed distal embolization, especially in patients with acute coronary syndrome. So, despite stent use, we may observe distal embolization in patients with acute coronary syndromes. Sdringola, et al detected four independent risk factors for no reflow/slow flow phenomenon as probable thrombus, acute coronary syndromes, degenerated vein graft, and ulcer.
26) The PAMI-2 trial results also support our results. In the PAMI-2 trial, when percutaneous angioplasty was attempted to bypass a graft infarct vessel in patients with acute MI, TIMI flow grade 3 was restored in only 70% of the bypass grafts, as compared to 94% of native coronary arteries (P < 0.0001). The reason for this difference was explained in terms of an extensive thrombus and an atherosclerosis burden in bypass grafts and increased rate of distal embolization. 27) In the present study, the glycoprotein IIb/IIIa inhibitor tirofiban was used in 27 (56%) patients. In 5 patients with distal embolization, only 1 had received the glycoprotein IIb/IIIa inhibitor. Although we could not detect a relation between distal embolization and glycoprotein IIb/IIIa inhibitor use, glycoprotein IIb/IIIa inhibitor use may be protective with respect to distal embolization. Some reports have evaluated the effects of glycoprotein IIb/IIIa inhibitors during percutaneous interventions of SVGs. Mak, et al studied the IIb/IIIa platelet receptor antagonist 7E3 in the Preventing Ischemic Complications (EPIC) trial and evaluated the efficacy of glycoprotein IIb/IIIa inhibitors in reducing distal embolization, non-Q wave MI, and restenosis in patients undergoing percutaneous revascularization of SVGs. They concluded that abciximab therapy during percutaneous treatment of SVGs reduces the occurrence of distal embolization and possibly non-Q wave MI. 28) Also, some smaller studies have showed that glycoprotein IIb/IIIa inhibitors reduce the thrombus burden in SVGs lesions and may decrease distal embolization during percutaneous interventions. [29] [30] [31] In the present study, since the study group was small and glycoprotein IIb/IIIa inhibitor use was limited, we were unable to definitively conclude that glycoprotein IIb/IIIa inhibitors reduced distal embolization. Large-scale, randomized studies should be performed to clarify this.
Kuroda, et al reported that, after stenting of SVGs in 51 consecutive patients, lesion length and total cholesterol levels are independent predictors of distal embolization. 21) We could not detect any relationships between distal embolization and hypercholesterolemia and lesion length.
In the present study, target lesion revascularization was conducted in 11 (23%) patients. Restenosis was observed particularly in patients with diabetes mellitus, hypercholesterolemia, and acute coronary syndrome. Kuroda, et al found that angiographic restenosis at 6 months occurred in 26.5% of the lesions. The poststenting minimum luminal diameter and percent diameter stenosis are predictors of restenosis. 21) In the Multicenter US Palmaz-Schatz Stent Experiences, the procedural success rate was 97.1%, the restenosis rate was 29.7% in a 6-month angiographic follow-up, and independent predictors of restenosis were restenotic lesions, a smaller reference vessel size, a history of diabetes mellitus, and higher percent poststenting diameter stenosis. 7) We did not observe any no reflow/slow flow during percutaneous angioplasty to ISR lesions of SVGs. The reason for this difference in ISR lesions from de novo lesions of SVGs may be explained by the pathology of ISR lesions. Instent restenosis lesions are pathologically distinct from de novo lesions. In degenerated SVGs, the de novo lesions had friable atherogenic material. However, ISR lesions occur due to neointimal proliferation which is composed of proliferating smooth muscle cells and extracellular matrix. 32) Therefore, the risk of distal embolization is expected to be lower after percutaneous intervention of ISR of SVGs compared to that of de novo SVG lesions. Ashby, et al also detected no episodes of no reflow/slow flow phenomenon during percutaneous intervention of ISR of SVGs without distal protection and concluded that distal embolic protection may not be necessary during percutaneous intervention of ISR of SVGs. 18) However, in the present study, among patients with ISR, none had acute MI, and only 3 patients had unstable angina pectoris. During the stenting of de novo SVG lesions, 14 patients had acute coronary syndrome. Since acute coronary syndrome is an important risk factor for distal embolization, this may also have con- tributed to the different incidences of distal embolization between stenting to SVG and angioplasty to ISR.
In-stent restenosis is a major problem for SVGs as it is for native coronary arteries and new treatment modalities have been improved for treatment. Some studies have shown that radiation therapy alone or radiation therapy with excimer laser coronary angioplasty may reduce angiographic restenosis and improve event-free survival. 9, 33, 34) Membrane-covered stents may potentially reduce ISR in obstructed SVGs. 35) As a result, stent implantation in patients with de novo SVG lesions can be achieved with high rates of angiographic and procedural success. Distal embolization was observed, especially in patients with acute coronary syndrome. Restenosis was observed, particularly in patients with diabetes mellitus, hypercholesterolemia, and acute coronary syndrome. The risk of distal embolization is lower during percutaneous angioplasty of ISR lesions of SVGs compared to stenting of de novo SVG lesions. Study limitations: This study is a retrospective and nonrandomized observational study from a single center. The study group may have been subject to selection bias. Routine angiographic follow-up was not obtained to assess the true angiographic restenosis rate. Since the number of patients is relatively small, larger prospective studies should be undertaken.
